BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 3.93 (+0.03), CAPR: 6.68 (+0.09), BMRN: 122.78 (+0.13), RNA: 18.65 (unch), PFE: 33.99 (+0.05), SRPT: 15.21 (-0.11), PTCT: 52.09 (-2.24), SMMT: 10.13 (-0.37)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 391.24 (-3.11), VRTX: 126.21 (+3.21), PRGO: 194.50 (+0.35), PFE: 33.99 (+0.05), CLDN: 2.18 (-0.17), MYL: 70.67 (-0.86), OREX: 5.01 (unch), JNJ: 102.30 (+0.47), NVO: 56.75 (+0.06), TNXP: 6.35 (+0.01), ALNY: 119.84 (+3.97), GILD: 109.30 (+0.56), SGEN: 39.94 (-0.30), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), GALE: 1.35 (-0.01), JUNO: 43.37 (-1.52), SNY: 50.52 (-0.27), NBY: 0.62 (+0.02), XLRN: 31.84 (-0.02)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 122.78 (+0.13), SRPT: 15.21 (-0.11), PTCT: 52.09 (-2.24)